SERPATE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for SERPATE (SERPATE).
Selective serotonin reuptake inhibitor (SSRI); inhibits serotonin reuptake at the presynaptic neuron, enhancing serotonergic neurotransmission.
| Metabolism | Hepatic primarily via CYP2C19, CYP2D6, CYP3A4, and CYP2C9; active metabolite desmethylsertraline. |
| Excretion | Primarily renal excretion of unchanged drug (60-80%); biliary/fecal elimination accounts for 15-20%. |
| Half-life | Terminal half-life of 12-15 hours (range 10-18h) in adults; prolonged in renal impairment (up to 30h in severe cases). |
| Protein binding | 95-98% bound, primarily to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.5-0.7 L/kg (suggests moderate tissue penetration; primarily extracellular distribution). |
| Bioavailability | Oral: 70-80% (first-pass metabolism 20-30%; food reduces absorption by 10-15%). |
| Onset of Action | Oral: 30-60 minutes; IV: 2-5 minutes. |
| Duration of Action | Oral: 6-12 hours; IV: 4-6 hours. Duration extended in hepatic or renal impairment. |
50 mg orally once daily.
| Dosage form | TABLET |
| Renal impairment | No dosage adjustment required for GFR ≥30 mL/min; GFR <30 mL/min: not recommended. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: 25 mg once daily; Child-Pugh C: not recommended. |
| Pediatric use | Not approved for pediatric use. |
| Geriatric use | No dosage adjustment required; monitor renal function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for SERPATE (SERPATE).
| Breastfeeding | SERPATE is excreted into human breast milk. Milk-to-plasma ratio is approximately 2:1. Breastfeeding is not recommended during therapy due to potential for severe adverse reactions in the nursing infant. Advise women to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. |
| Teratogenic Risk | SERPATE is contraindicated in pregnancy. First trimester exposure carries risk of major congenital malformations including neural tube defects and cardiovascular anomalies. Second and third trimester exposure may cause fetal growth restriction and oligohydramnios. For all trimesters, increased risk of spontaneous abortion and stillbirth has been reported. |
■ FDA Black Box Warning
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
| Serious Effects |
["Concurrent MAOIs (including linezolid and methylene blue)","Concurrent pimozide","Known hypersensitivity to sertraline"]
| Precautions | ["Suicidality risk in pediatric/young adult patients","Serotonin syndrome risk with concomitant serotonergic drugs","Bleeding risk with anticoagulants/antiplatelets","Activation of mania/hypomania","Seizure risk in patients with epilepsy","Angle-closure glaucoma risk","Hyponatremia risk in elderly/dehydrated patients","Discontinuation syndrome with abrupt cessation"] |
Loading safety data…
| Fetal Monitoring | In pregnant women exposed to SERPATE, monitor fetal growth via ultrasound every 4 weeks. Perform serial amniotic fluid volume assessments. Evaluate for fetal malformations with detailed anatomy scan at 18–20 weeks. Monitor mother for signs of preeclampsia and hepatic dysfunction. After delivery, monitor neonate for withdrawal symptoms and respiratory depression. |
| Fertility Effects | SERPATE may impair female fertility based on animal studies showing disruption of estrous cycles and reduced ovarian follicle counts. In males, decreased sperm motility and morphology have been observed. Reversibility is unknown. Advise patients planning pregnancy of potential fertility risks. |